🇺🇸 FDA
Pipeline program

Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP), Lyophilized powder for reconstitution, Voxzogo 1.2 mg powder and solvent for solution for injection

111-210

Phase 2 small_molecule active

Quick answer

Voxzogo 0.56 mg powder and solvent for solution for injection, modified recombinant human C-type natriuretic peptide (rhCNP), Lyophilized powder for reconstitution, Voxzogo 1.2 mg powder and solvent for solution for injection for Idiopathic Short Stature (ISS) is a Phase 2 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
BioMarin International Limited
Indication
Idiopathic Short Stature (ISS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials